Esperion partners with CSL Seqirus to commercialize NEXLETOL, NEXLIZET

Esperion (ESPR) Therapeutics announced it has entered into a license and distribution agreement with CSL Seqirus for the exclusive rights to commercialize NEXLETOL and NEXLIZET in Australia and New Zealand. Under the terms of the agreement, Esperion will receive an upfront and near-term milestone payments and will be responsible for supplying finished product to CSL Seqirus at a profitable transfer price. “We are excited to partner with CSL Seqirus to provide physicians and patients with additional options to treat high LDL-C cholesterol and reduce the risk of cardiovascular disease in Australia and New Zealand,” said Sheldon Koenig, President and CEO of Esperion. “This partnership expands the reach of our potentially lifesaving medications to another large market, further enhancing our global reach.”